This is a working overview of glucagon receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-24. Anything still debated is marked as such rather than presented as settled.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
=== Sterilization of biomedical materials === Supercritical CO2 is an alternative for thermal sterilization of biological materials and medical devices with combination of the additive peracetic acid (PAA). Supercritical CO2 does not sterilize the media, because it does not kill the spores of microorganisms. Moreover, this process is gentle, as the morphology, ultrastructure and protein profiles of inactivated microbes are preserved.
=== Low-throughput === The mentioned drawbacks limit the reasonable use of automated in-gel digestion systems to the routine laboratory whereas the research laboratory with a demand to make a flexible use of the instruments of protein identification more often stays with the manual, low-throughput methods for in-gel digestion and MS analysis. This group of customers is targeted by the industry with several kit systems for in-gel digestion. Most of the kit systems are mere collections of the chemicals and enzymes needed for the in-gel digestion whereas the underlying protocol remains unchanged from the manual standard procedure described above. The advantage of these products for the inexperienced customer lies in the guaranteed functioning of the diverse solutions in combination with a ready-made protocol for the process. A few companies have tried to improve the handling process of in-gel digestion to allow even with manual sample preparation an easier and more standardised workflow. The Montage In-Gel Digest Kit from Millipore is based on the standard protocol, but enables processing of a large number of parallel samples by transferring the handling of the gel pieces to a modified 96 well microplate. The solutions for the diverse steps of in-gel digestion are pipetted into the wells of this plate whereas the removal of liquids is performed through the bottom of the wells by a vacuum pump. This system simplifies the handling of the multiple pipetting steps by the use of multichannel pipettes and even pipetting robots.
== Chromatography == Mikhail Tsvet invented chromatography in 1900 during his research on plant pigments. He used liquid-adsorption column chromatography with calcium carbonate as adsorbent and petrol ether/ethanol mixtures as eluent to separate chlorophylls and carotenoids. The method was described on 30 December 1901 at the XI Congress of Naturalists and Physicians (XI съезд естествоиспытателей и врачей) in St. Petersburg. The first printed description was in 1905, in the Proceedings of the Warsaw Society of Naturalists, biology section. He first used the term "chromatography" in print in 1906 in his two papers about chlorophyll in the German botanical journal, Berichte der Deutschen botanischen Gesellschaft. In 1907, he demonstrated his chromatograph for the German Botanical Society. For several reasons, Tsvet's work was long ignored: the violent political upheaval in Russia at the beginning of the 20th century, the fact that Tsvet originally published only in Russian (making his results largely inaccessible to western scientists), and an article denying Tsvet's findings. Richard Willstätter and Arthur Stoll tried to repeat Tsvet's experiments, but because they used an overly aggressive adsorbent (destroying the chlorophyll), they were not able to do so. They published their results, and Tsvet's chromatography method fell into obscurity. It was revived 10 years after his death thanks to Austrian biochemist Richard Kuhn and his student, German scientist Edgar Lederer as well as the work of A. J. Martin and R. L. Synge.
Sources: en.wikipedia.org
The Nelson brothers, butchers in County Meath, Ireland, started shipping extensive live beef shipments to Liverpool, England. They successfully expanded their beef business until their imports from Ireland were insufficient to supply their rapidly growing business and Nelson decided to investigate the possibility of importing meat from Argentina. The first refrigerated ship they bought was Spindrift which they renamed in 1890 SS Highland Scot. A vessel of 3,060 gross tons bought by James Nelson and Sons in 1889 and fitted with a somewhat primitive refrigerating plant operating on the cold air system became one of the pioneer vessels in the trade of refrigerated meat and other perishable commodities. They hauled beef carcasses from Argentina to Britain. Their regularly scheduled shipments and ships developed into the Nelson Line that was formed in 1880 for the meat trade from Argentina to UK. Refrigeration made it possible to import meat from the United States, New Zealand, Argentina and Australia.
There are three major regions that center around drug trafficking, known as the Golden Triangle (Burma, Laos, Thailand), Golden Crescent (Afghanistan) and Central and South America. There are suggestions that due to the continuing decline in opium production in South East Asia, traffickers may begin to look to Afghanistan as a source of heroin." With respect to organized crime and accelerating synthetic drug production in East and Southeast Asia, especially the Golden Triangle, Sam Gor, also known as The Company, is the most prominent international crime syndicate based in Asia-Pacific. It is made up of members of five different triads. Sam Gor is understood to be headed by Chinese-Canadian Tse Chi Lop. The Cantonese Chinese syndicate is primarily involved in drug trafficking, earning at least $8 billion per year. Sam Gor is alleged to control 40% of the Asia-Pacific methamphetamine market, while also trafficking heroin and ketamine. The organization is active in a variety of countries, including Myanmar, Thailand, New Zealand, Australia, Japan, China and Taiwan. Sam Gor previously produced meth in Southern China and is now believed to manufacture mainly in the Golden Triangle, specifically Shan State, Myanmar, responsible for much of the massive surge of crystal meth in recent years. The group is understood to be headed by Tse Chi Lop, a Chinese-Canadian gangster born in Guangzhou, China. Tse is a former member of the Hong Kong-based crime group, the Big Circle Gang. In 1988, Tse immigrated to Canada.
The common name birch comes from Old English birce, bierce, from Proto-Germanic *berk-jōn (cf. German Birke, West Frisian bjirk), an adjectival formation from *berkōn (cf. Dutch berk, Low German Bark, Danish birk, Norwegian bjørk), itself from the Proto-Indo-European root *bʰerHǵ- ~ bʰrHǵ-, which also gave Lithuanian béržas, Latvian Bērzs, Russian берёза (berëza), Ukrainian береза (beréza), Albanian bredh 'fir', Ossetian bærz(æ), Sanskrit bhurja, Polish brzoza, Czech bříza, Slovak breza. This root is presumably derived from *bʰreh₁ǵ- 'to shine, whiten', in reference to the birch's white bark. The Proto-Germanic rune berkanan is named after the birch. The generic name Betula is from Latin, which is a diminutive borrowed from Gaulish betua (cf. Old Irish bethe, Welsh bedw).
Sources: en.wikipedia.org
The classic symptoms of diabetes are frequent urination (polyuria), increased thirst (polydipsia), increased hunger (polyphagia), and weight loss. Other symptoms may include blurred vision, itchiness, peripheral neuropathy, recurrent vaginal infections, and fatigue, as well as loss of taste. Many people, however, have no symptoms during the first few years and are diagnosed on routine testing. A small number of people with type 2 diabetes can develop a hyperosmolar hyperglycemic state (a condition of very high blood sugar associated with a decreased level of consciousness and low blood pressure).
Courtship in teleosts plays a role in species recognition, strengthening pair bonds, spawning site position and gamete release synchronisation. This includes colour changes, sound production and visual displays (fin erection, rapid swimming, breaching), which is often done by the male. Courtship may be done by a female to overcome a territorial male that would otherwise drive her away.
Tidepool is a non-profit software organisation founded in 2013 in San Francisco, California, which develops open-source tools to help people manage diabetes. Its work spans data visualisation platforms for diabetes device data and, most notably, Tidepool Loop, an open-source automated insulin delivery (AID) system. The organisation works with device manufacturers including Medtronic and Dexcom to support interoperability across insulin pumps and continuous glucose monitors.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.